Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Bressler · SciRah

Researcher profile · Semantic Scholar

B. Bressler

Share profile

B. Bressler — researcher profile on SciRah

h-index: 45
Works: 332
Citations: 9,981

Most-cited papers

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
K. Papamichael, A. Cheifetz, G. Melmed, P. Irving +12 more
2019Clinical Gastroenterology and Hepatology329 citations Open access
Semantic Scholar
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study
B. Bressler, A. Yarur, M. Silverberg, M. Bassel +15 more
2021Journal of Crohn's & Colitis124 citations Open access
Semantic Scholar
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
L. Peyrin-Biroulet, J. Allegretti, D. Rubin, B. Bressler +159 more
2023Gastroenterology91 citations Open access
Semantic Scholar
Suppressive and Gut Reparative Functions of Human Type 1 T-regulatory Cells.
Laura Cook, M. Stahl, Xiao Han, A. Nazli +10 more
2019Gastroenterology90 citations Open access
Semantic Scholar
Vedolizumab for the Treatment of Chronic Pouchitis.
S. Travis, M. Silverberg, S. Danese, P. Gionchetti +10 more
2023New England Journal of Medicine87 citations Open access
Semantic Scholar
International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey
D. Rubin, C. Sninsky, B. Siegmund, M. Sans +5 more
2021Inflammatory Bowel Diseases84 citations Open access
Semantic Scholar
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease.
Christopher Ma, J. Hanžel, R. Panaccione, W. Sandborn +48 more
2022Gastroenterology72 citations Open access
Semantic Scholar
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
S. Vermeire, P. Lakatos, T. Ritter, S. Hanauer +13 more
2021The Lancet Gastroenterology and Hepatology61 citations Open access
Semantic Scholar
Is there an optimal sequence of biologic therapies for inflammatory bowel disease?
B. Bressler
2023Therapeutic Advances in Gastroenterology60 citations Open access
Semantic Scholar
Time to revisit disease classification in IBD: is the current classification of IBD good enough for optimal clinical management?
B. Verstockt, B. Bressler, H. Martinez-Lozano, Dermot T. McGovern +1 more
2021Gastroenterology52 citations
Semantic Scholar
REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis
Christopher Ma, R. Panaccione, Ya-Si Xiao, Yuvan Khandelwal +12 more
2022American Journal of Gastroenterology38 citations Open access
Semantic Scholar
Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program
G. Lichtenstein, B. Bressler, C. Francisconi, S. Vermeire +8 more
2022Inflammatory Bowel Diseases37 citations Open access
Semantic Scholar
PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis.
W. Sandborn, L. Mattheakis, N. Modi, D. Pugatch +12 more
2021Gastroenterology34 citations Open access
Semantic Scholar
Analysis of Flagellin-Specific Adaptive Immunity Reveals Links to Dysbiosis in Patients With Inflammatory Bowel Disease
Laura Cook, D. Lisko, May Q. Wong, Rosa V. Garcia +5 more
2019Cellular and Molecular Gastroenterology and Hepatology32 citations Open access
Semantic Scholar
Clinical Practice Guideline for the Management of Luminal Crohn's Disease: The Toronto Consensus.
R. Panaccione, A. Steinhart, B. Bressler, R. Khanna +20 more
2019Clinical Gastroenterology and Hepatology29 citations Open access
Semantic Scholar
Interleukin-37 regulates innate immune signaling in human and mouse colonic organoids
J. Allaire, A. Poon, S. Crowley, Xiao Han +8 more
2020Scientific Reports27 citations Open access
Semantic Scholar
Pharmacological inhibition of RORC2 enhances human Th17-Treg stability and function.
D. Boardman, Rosa V. Garcia, S. Ivison, B. Bressler +3 more
2020European Journal of Immunology22 citations Open access
Semantic Scholar
Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
B. Bressler, Jennifer Jones, T. S. In, Tommy Lan +2 more
2023Advances in Therapy15 citations
Semantic Scholar
Ustekinumab Therapeutic Drug Monitoring—Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial
W. Afif, B. Sattin, D. Dajnowiec, R. Khanna +6 more
2021Digestive Diseases and Sciences14 citations Open access
Semantic Scholar
Transition Readiness in Youth with Inflammatory Bowel Disease.
A. Foster, J. Chan, E. Wine, W. El-Matary +16 more
2023Jornal de Pediatria12 citations
Semantic Scholar
Do You See What I See? An Assessment of Endoscopic Lesions Recognition and Description by Gastroenterology Trainees and Staff Physicians
L. Hart, M. Chavannes, P. Lakatos, W. Afif +3 more
2019Journal of the Canadian Association of Gastroenterology12 citations Open access
Semantic Scholar
Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study.
R. Khanna, Christopher Ma, M. Hogan, G. Zou +20 more
2023Clinical Gastroenterology and Hepatology11 citations Open access
Semantic Scholar
An automated mass spectrometric blood test for therapeutic drug monitoring of infliximab.
J. Grace van der Gugten, B. Bressler, Mari L. DeMarco
2019Clinical Mass Spectrometry10 citations Open access
Semantic Scholar
OP04 Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial
S. Travis, M. Silverberg, S. Danese, P. Gionchetti +8 more
2022Journal of Crohn's & Colitis8 citations
Semantic Scholar
Providing Hospitalized Ulcerative Colitis Patients With Practice Guidelines Improves Patient-Reported Outcomes
A. Weizman, B. Bressler, C. Seow, W. Afif +7 more
2020Journal of the Canadian Association of Gastroenterology7 citations Open access
Semantic Scholar
De‐escalating medical therapy in Crohn’s disease patients who are in deep remission: A RAND appropriateness panel
M. Sparrow, G. Melmed, S. Devlin, P. Kozuch +12 more
2019GastroHep6 citations Open access
Semantic Scholar
913b THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
J. Allegretti, L. Peyrin-Biroulet, B. Feagan, B. Bressler +11 more
2023Gastroenterology5 citations
Semantic Scholar
Has the time come to say goodbye to therapeutic drug monitoring as we know it?
B. Bressler, A. Steinhart
2022Gastroenterology5 citations Open access
Semantic Scholar
OP08 Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial
V. Jairath, B. Feagan, M. Silverberg, S. Danese +10 more
2023Journal of Crohn's & Colitis4 citations Open access
Semantic Scholar
Impact of Telehealth on Medication Adherence in Chronic Gastrointestinal Diseases
Hyun Jae Kim, M. Tomaszewski, Billy Zhao, E. Lam +3 more
2022Journal of the Canadian Association of Gastroenterology4 citations Open access
Semantic Scholar
A Summary of the BRIDGe Summit on Damage-Related Progression of Ulcerative Colitis: Establishing Research Priorities
N. Cleveland, B. Bressler, C. Siegel
2022Gastroenterology4 citations Open access
Semantic Scholar
P393 Patient and physician perspectives on the management of inflammatory bowel disease: Role of steroids in the context of biologic therapy
A. Afzali, A. Armuzzi, Y. Bouhnik, B. Bressler +5 more
2020Journal of Crohn's & Colitis4 citations Open access
Semantic Scholar
DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE
G. Mantzaris, B. Bressler, U. Kopylov, M. Bassel +11 more
20204 citations Open access
Semantic Scholar
P685 Improvement in patient-reported Inflammatory Bowel Disease Questionnaire outcomes, and relationship with disease activity, in tofacitinib-treated patients with ulcerative colitis: Data from the OCTAVE clinical trials
M. Dubinsky, B. Bressler, A. Armuzzi, L. Salese +5 more
2019Journal of Crohn's & Colitis4 citations Open access
Semantic Scholar
Development of a Global Rating Scale for Inflammatory Bowel Disease
A. Bitton, K. S. Devitt, B. Bressler, J. Heatherington +7 more
2019Journal of the Canadian Association of Gastroenterology4 citations Open access
Semantic Scholar
P584 Efficacy, safety, and tolerability of AMT-101, a gut selective oral IL-10 fusion, in the Phase 2 FILLMORE trial of patients with chronic pouchitis
V. Jairath, B. Bressler, M. Silverberg, L. Lee +8 more
2023Journal of Crohn's & Colitis3 citations Open access
Semantic Scholar
P482 Patient and physician perspectives on the management of inflammatory bowel disease: Disease remission and durability of treatment
A. Afzali, A. Armuzzi, Y. Bouhnik, B. Bressler +5 more
20203 citations Open access
Semantic Scholar
795 Real World Safety of Vedolizumab and Anti-TNF Therapies in Biologic-Naïve Ulcerative Colitis and Crohn's Disease Patients: Results From the EVOLVE Study
A. Yarur, G. Mantzaris, U. Kopylov, M. Bassel +9 more
2019American Journal of Gastroenterology3 citations
Semantic Scholar
A True Residual Bias: Did the Exacerbation Truly Precede NSAID Exposure?
Elizabeth Squirell, B. Bressler
2023American Journal of Gastroenterology2 citations
Semantic Scholar
P777 Deployment of an artificial intelligence tool for precision medicine in ulcerative colitis: Preliminary data from 8 globally distributed clinical sites
L. Peyrin-Biroulet, D. Rubin, C. Weber, S. Adsul +17 more
2023Journal of Crohn's & Colitis2 citations Open access
Semantic Scholar
A175 REAL-WORLD EXPERIENCE ON SWITCHING FROM ADALIMUMAB TO BIOSIMILARS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE – AN OBSERVATIONAL STUDY FROM THREE TERTIARY CARE CENTRES
H. Bedi, D. Rosenfeld, T. Hoang, M. Reise-Filteau +4 more
2023Journal of the Canadian Association of Gastroenterology2 citations Open access
Semantic Scholar
S869 Real World Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-Naïve Patients With Crohn’s Disease: Results From the EVOLVE Study
B. Bressler, N. Brett, M. Bassel, S. Adsul +2 more
2022American Journal of Gastroenterology2 citations
Semantic Scholar
An Expert Consensus to Standardize Assessment of Bowel Cleansing for Clinical Trials of Bowel Preparations for Crohn’s Disease
J. Maratt, C. Siegel, A. Barkun, Y. Bouhnik +18 more
2022Digestive Diseases and Sciences2 citations
Semantic Scholar
DOP60 Simplified rules to identify bio-naïve patients with Crohn’s Disease with higher likelihood of clinical remission when initiating vedolizumab versus anti-TNFα therapies: Analysis of EVOLVE study data
G. Mantzaris, A. Yarur, S. Wang, S. Adsul +6 more
20212 citations
Semantic Scholar
Clinician perspectives on the use of artificial intelligence in inflammatory bowel disease.
G. Nigam, Rajan N. Patel, B. Bressler, Ha-Yee Bu +3 more
2021Gastrointestinal Endoscopy2 citations Open access
Semantic Scholar
Impaired Th17 immunity in recurrent C. difficile infection is ameliorated by fecal microbial transplantation
Laura Cook, W. Rees, May Q. Wong, Xiao-Jiao Wang +11 more
2020medRxiv2 citations Open access
Semantic Scholar
Letter: corticosteroid use alongside tofacitinib in OCTAVE Open
Bruce E. Sands, A. Armuzzi, J. Marshall, James O. Lindsay +13 more
2020Alimentary Pharmacology and Therapeutics2 citations Open access
Semantic Scholar
Sa1748 CLINICAL EFFECTIVENESS AND SAFETY OF FIRST-LINE BIOLOGIC VEDOLIZUMAB AS A MONOTHERAPY OR COMBINATION THERAPY IN ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS: RESULTS FROM THE EVOLVE STUDY
B. Bressler, A. Yarur, U. Kopylov, M. Bassel +11 more
20202 citations
Semantic Scholar
Mo1811 REAL-WORLD CLINICAL OUTCOMES OF BIOLOGIC-NAÏVE NONCOMPLICATED CROHN'S DISEASE PATIENTS TREATED WITH VEDOLIZUMAB: RESULTS FROM THE EVOLVE STUDY
A. Yarur, G. Mantzaris, U. Kopylov, M. Bassel +11 more
2020Gastroenterology2 citations Open access
Semantic Scholar
P419 Clinical effectiveness and safety of first-line biologic vedolizumab as a monotherapy or combination therapy in ulcerative colitis and Crohn’s disease patients: results from the EVOLVE study
B. Bressler, A. Yarur, U. Kopylov, M. Bassel +11 more
20202 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

G. Mantzaris×8
Invite
G. Mantzaris — researcher profile on SciRah
B. Feagan×8
Invite
B. Feagan — researcher profile on SciRah
S. Danese×8
Invite
S. Danese — researcher profile on SciRah
A. Yarur×7
Invite
A. Yarur — researcher profile on SciRah

×7

Invite

M. Silverberg — researcher profile on SciRah

Invite

M. Bassel — researcher profile on SciRah

Invite

U. Kopylov — researcher profile on SciRah

Jennifer Jones×6

Invite

Jennifer Jones — researcher profile on SciRah

Invite

D. Demuth — researcher profile on SciRah

Invite

V. Jairath — researcher profile on SciRah

Invite

S. Adsul — researcher profile on SciRah

Invite

C. Siegel — researcher profile on SciRah